Dr. Benjamin P. Levy, MD
Hematology & Oncology (Hematology & Oncology Physician)
9910 Franklin Square Dr Ste 2110
Baltimore, MD 21236
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D82526 · NY license 240367
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sibley Memorial Hospital Washington, DC
Medical groups
- Johns Hopkins University (2,909 clinicians)
- Johns Hopkins University (197 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 916
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 518 | 139 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 41 |
| Dexamethasone Other prescribers in Baltimore, MD | 23 |
| Prochlorperazine Maleate Other prescribers in Baltimore, MD | 23 |
| Alecensa (alectinib hcl) | 18 |
| Levothyroxine Sodium Other prescribers in Baltimore, MD | 18 |
| Ondansetron Hcl Other prescribers in Baltimore, MD | 17 |
| Xarelto (rivaroxaban) Other prescribers in Baltimore, MD | 15 |
| Tabrecta (capmatinib hydrochloride) | 12 |
| Mekinist (trametinib dimethyl sulfoxide) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 20 payments worth $14,178 in total to this clinician.
| Pfizer Inc. | $3,435 |
|---|---|
| Aadi Bioscience, Inc. | $3,325 |
| AstraZeneca Pharmaceuticals LP | $2,782 |
| Janssen Biotech, Inc. | $1,691 |
| Novartis Pharmaceuticals Corporation | $1,688 |
| Gilead Sciences, Inc. | $760 |
| Daiichi Sankyo Inc. | $414 |
| Jazz Pharmaceuticals Inc. | $83.63 |
| Consulting Fee | $11,488 |
|---|---|
| Food and Beverage | $1,146 |
| Compensation for services other than consulting (speaking, faculty) | $1,125 |
| Travel and Lodging | $419 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aadi Bioscience, Inc. Jun 18, 2025 | Consulting Fee Fyarro · Cancer | $2,400 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Consulting Fee | $1,688 |
| Janssen Biotech, Inc. Nov 5, 2025 | Consulting Fee RYBREVANT · Oncology | $1,670 |
| Pfizer Inc. Nov 24, 2025 | Consulting Fee | $1,540 |
| Pfizer Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) LORBRENA · ONCOLOGY | $1,125 |
| AstraZeneca Pharmaceuticals LP Jun 23, 2025 | Consulting Fee | $998 |
| AstraZeneca Pharmaceuticals LP Oct 4, 2025 | Consulting Fee DATROWAY · Oncology | $998 |
| Pfizer Inc. Jul 8, 2025 | Consulting Fee | $770 |
| Gilead Sciences, Inc. Jun 11, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4308216;GTF;10888736 | $760 |
| AstraZeneca Pharmaceuticals LP Jan 24, 2025 | Consulting Fee | $665 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 24, 2025 | Consulting Fee | $1,540 |
| Janssen Biotech, Inc. Nov 5, 2025 | Consulting Fee RYBREVANT · Oncology | $1,670 |
| AstraZeneca Pharmaceuticals LP Oct 4, 2025 | Consulting Fee DATROWAY · Oncology | $998 |
| Pfizer Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) LORBRENA · ONCOLOGY | $1,125 |
| Pfizer Inc. Jul 8, 2025 | Consulting Fee | $770 |
| AstraZeneca Pharmaceuticals LP Jun 23, 2025 | Consulting Fee | $998 |
| Aadi Bioscience, Inc. Jun 18, 2025 | Consulting Fee Fyarro · Cancer | $2,400 |
| Aadi Bioscience, Inc. Jun 18, 2025 | Travel and Lodging Fyarro · Cancer · travel to New York, NY | $419 |
| Gilead Sciences, Inc. Jun 11, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4308216;GTF;10888736 | $760 |
| AstraZeneca Pharmaceuticals LP Jan 24, 2025 | Consulting Fee | $665 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Consulting Fee | $1,688 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $220,609 in research payments for these studies, mostly to the institutions running them.
- Zongertinib Out of Scope / Named Patient Use requests
Boehringer Ingelheim Pharma GmbH & Co.kg - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo…
AstraZeneca Pharmaceuticals LP - A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company · Active, not recruiting · NCT03157128 - A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment…
AstraZeneca Pharmaceuticals LP - A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.